+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 4 Actively Recruiting clinical trials

S

Actively Recruiting

Healthy Volunteer

Respiratory syncytial virus RSV is a common virus affecting children, especially young babies, premature infants, and those with heart or lung problems. It is a leading cause of hospitalization for children under 5 years old globally, with many severe cases and deaths occurring in low- and middle-income countries. This research evaluates the safety of an RSV vaccine called ABRYSVO given to pregnant women and how well it protects their infants from severe RSV infections during the first six months of life, particularly in African and lower-middle income countries where data is limited. Pregnant women will receive either the ABRYSVO vaccine or a placebo in a randomized, double-blind trial. The vaccine contains stabilized RSV prefusion F antigens from virus subgroups A and B. The study will enroll pregnant women at the approved gestational age for vaccination, with participants randomly assigned to receive either the vaccine or placebo in equal numbers. The trial will monitor the safety of the vaccine in mothers and infants and measure how well the vaccine prevents severe RSV lower respiratory tract infections in babies up to 180 days old. Participants will attend antenatal clinics and provide informed consent for themselves and their infants. Researchers will follow the women through pregnancy and delivery, recording any preterm births and birth weights. Infants will be monitored for RSV infections confirmed by laboratory tests, and hospitalizations due to RSV will be tracked up to six months of age. Safety assessments include monitoring adverse events in mothers and babies, with follow-up visits and telephone contacts to ensure comprehensive data collection throughout the trial period.

Age: 14Years - 55YearsFEMALEPhase 3
11 locations
P

Actively Recruiting

Healthy Volunteer

Researchers are evaluating the safety, immune response, and preliminary clinical efficacy of a candidate vaccine for urinary tract infections UTIs in adults aged 18 to 64 years. This trial focuses on adults generally for safety and immune response, and specifically on females with a history of at least one confirmed E. coli UTI within the past year for clinical efficacy. The study includes two parts an initial dose-escalation safety phase and a proof-of-principle efficacy phase, designed to establish the highest tolerated dose and evaluate the vaccines impact on UTI occurrence. Participants receive one of several vaccine dose formulations or placebo administered by injection on Day 1 and Day 61. Part 1 involves healthy male and female adults and tests increasing antigen doses for safety. After safety review, Part 2 enrolls females with previous E. coli UTIs to assess vaccine efficacy compared to placebo over a 12-month period. The vaccine is given intramuscularly following a 0 and 2 months schedule. Throughout the study, participants are monitored for side effects at the injection site and systemic reactions during the first week after each dose, as well as for any adverse events up to 426 days from the first dose. Blood tests, pregnancy monitoring, and clinical exams are conducted. The main outcome measures include the frequency of adverse events and the rate of urine culture confirmed UTIs in females during the follow-up period. Participants are followed closely for safety and immune response, with the trial lasting over a year from initial vaccination.

Age: 18Years - 64YearsAll GendersPhase 1Phase 2
8 locations
P

Actively Recruiting

Healthy Volunteer

Researchers are evaluating the safety and immune response of the MTBVAC vaccine in adolescents and adults aged 12 to 55 years, both living with and without HIV in South Africa. This Phase 2a clinical trial aims to compare MTBVAC with the BCG vaccine in participants grouped based on their HIV status, CD4 T cell count, and interferon-gamma release assay IGRA status. The study is conducted by the HIV Vaccine Trials Network and involves randomized assignment without a placebo group. Participants will receive a single intradermal injection of either MTBVAC or BCG vaccine, each at a volume of 0.1 mL, administered in the upper arm at the start of the study. The study is divided into two parts and three cohorts, with enrollment proceeding sequentially based on safety criteria. Follow-up will continue for 48 weeks after vaccination to monitor safety and immune responses. During the study, participants will undergo various assessments including monitoring for adverse events up to 48 weeks, measurement of specific immune cell responses at baseline and multiple time points, gene expression profiling, and antibody levels. Researchers will also evaluate the acceptability of the vaccines. Safety monitoring includes tracking serious and solicited adverse events, with a focus on immune markers such as CD4 and CD8 T cells expressing certain cytokines. Participants will be asked to attend scheduled visits for these assessments throughout the study period.

Age: 12Years - 55YearsAll GendersPhase 2
16 locations
E

Actively Recruiting

Researchers are evaluating the safety and effectiveness of two sorfequiline-based treatment regimens combined with pretomanid and linezolid for adults aged 18 to 65 with newly diagnosed, drug-sensitive, smear-positive pulmonary tuberculosis. This phase 2, randomized, multi-center, partially blinded trial involves about 100 participants in South Africa and Tanzania and aims to assess treatment safety and bacterial culture conversion times. Participants are randomly assigned to one of two oral treatment groups one receives a loading dose regimen of sorfequiline 200 mg daily for 4 weeks followed by 100 mg daily for 13 weeks, and the other receives sorfequiline 100 mg daily for 17 weeks. Both groups also take pretomanid 200 mg and linezolid 600 mg daily, with the treatment administered once daily with food. The trial includes a screening period up to 11 days before treatment, a 17-week treatment period, and a 52-week follow-up after treatment ends. During the study, participants will undergo safety monitoring including assessments of adverse events, ECGs, vital signs, lab tests, vision checks, and peripheral neuropathy evaluations. Researchers will also measure treatment efficacy by monitoring time to stable sputum culture conversion and treatment outcomes at 26 and 52 weeks post-treatment. Pharmacokinetics and quality of life are additionally assessed throughout the study duration.

Age: 18Years - 65YearsAll GendersPhase 2
12 locations